Millions of people who rely on blue inhalers to manage asthma attacks are being urged to contact their GP following updated medical guidelines. Research indicates that prolonged use of these inhalers may actually exacerbate the condition.
Understanding the Blue Inhaler
For decades, the blue inhaler—medically known as a short-acting beta2 agonist (SABA)—has been a lifeline for asthma sufferers. Containing salbutamol (e.g., Ventolin), it provides rapid relief by opening airways and relaxing muscles during attacks, wheezing, or chest tightness. However, the National Institute for Health and Care Excellence (NICE) has revised its guidance, recommending a shift away from blue inhalers, which it says mask symptoms without addressing the underlying issue.
New Guidelines and Risks
NICE warns that overuse of blue inhalers is linked to higher risks of attacks, hospital admissions, and death. In England, nearly half of blue inhaler users (48%) were prescribed more than two in 2024-2025—a level specialists consider a warning sign. Dr. Amina Al-Yassin, a GP and clinical lead for children and young people's services at Brent Integrated Care Partnership, stated: "They make people feel better, but only briefly. We now know that over time they are likely to make asthma worse. Seeing a blue inhaler used alone is now a dangerous sign to me."
Recommended Alternatives: Combination Inhalers
For optimal asthma control, individuals should experience minimal symptoms and rarely need reliever inhalers. The new guidelines advise people aged 12 and over who are newly diagnosed or require step-up treatment to transition to combination inhalers. These devices merge an inhaled steroid with a long-acting beta2 agonist (LABA) like formoterol, treating inflammation and preventing flare-ups while providing immediate relief. Two primary treatment plans are available:
- Anti-inflammatory Reliever (AIR): For those with symptoms less than twice a month, such as during pollen season or exercise.
- Maintenance and Reliever Therapy (MART): For individuals with more frequent or severe symptoms, using the inhaler daily and as needed.
Expert Endorsements
Professor Ewan Maule, director of medicines and pharmacy for North East and North Cumbria Integrated Care Board (ICB), explained: "For over 50 years, the blue inhaler has provided quick relief, but asthma involves controlling inflammation, not just opening airways. Upgrading to a combined treatment inhaler addresses the root cause, leading to fewer flare-ups, hospital visits, and better long-term lung health." Claire Adams, ICB respiratory clinical lead, added: "The new combination inhalers offer more protection and better control, helping people live well and breathe more easily. Reviewing your asthma action plan with a healthcare professional ensures you use the right inhaler correctly for optimal lung protection."
Action Required
The ICB advises: "Anyone currently using a blue reliever inhaler is encouraged to contact their GP practice to review their asthma plan and determine if a new combination inhaler might be more effective." For more information on switching from blue to new, consult your GP surgery.
